Full Product Details
Author: Mark Chang
Publisher: Springer-Verlag New York Inc.
Imprint: Springer-Verlag New York Inc.
Edition: 2011 ed.
Dimensions:
Width: 15.50cm
, Height: 1.70cm
, Length: 23.50cm
Weight: 0.498kg
ISBN: 9781461429456
ISBN 10: 1461429455
Pages: 307
Publication Date: 15 August 2013
Audience:
Professional and scholarly
,
Professional & Vocational
Format: Paperback
Publisher's Status: Active
Availability: Manufactured on demand
We will order this item for you from a manufactured on demand supplier.
Reviews
From the reviews: This is a first class book. It discusses a wide range of deep issues in statistics, and although focused on topics arising in biostatistics, pharmaceuticals, and clinical trials it would make stimulating and thought-provoking reading for any statistician. ... There are exercises at the end of each chapter, and I am certainly tempted to use the book as the basis for a short course for beginning postgraduate students ... since it would open their eyes to some challenging and indeed fascinating aspects of modern statistics. (David J. Hand, International Statistical Review, Vol. 80 (1), 2012)
From the book reviews: There are 10 chapters, each one covering a major topic in biostatistics in about 30 pages. Each chapter is reasonably self-contained, so a reader does not necessarily need to read all prior chapters to understand a given one. ... this is a useful book for upper-level graduate students and Ph.D. statisticians. (Charles Heckler, Technometrics, Vol. 55 (1), February, 2013) This is a first class book. It discusses a wide range of deep issues in statistics, and although focused on topics arising in biostatistics, pharmaceuticals, and clinical trials it would make stimulating and thought-provoking reading for any statistician. ... There are exercises at the end of each chapter, and I am certainly tempted to use the book as the basis for a short course for beginning postgraduate students ... since it would open their eyes to some challenging and indeed fascinating aspects of modern statistics. (David J. Hand, International Statistical Review, Vol. 80 (1), 2012)
From the book reviews: “There are 10 chapters, each one covering a major topic in biostatistics in about 30 pages. Each chapter is reasonably self-contained, so a reader does not necessarily need to read all prior chapters to understand a given one. … this is a useful book for upper-level graduate students and Ph.D. statisticians.” (Charles Heckler, Technometrics, Vol. 55 (1), February, 2013) “This is a first class book. It discusses a wide range of deep issues in statistics, and although focused on topics arising in biostatistics, pharmaceuticals, and clinical trials it would make stimulating and thought-provoking reading for any statistician. … There are exercises at the end of each chapter, and I am certainly tempted to use the book as the basis for a short course for beginning postgraduate students … since it would open their eyes to some challenging and indeed fascinating aspects of modern statistics.” (David J. Hand, International Statistical Review, Vol. 80 (1), 2012)
From the book reviews: There are 10 chapters, each one covering a major topic in biostatistics in about 30 pages. Each chapter is reasonably self-contained, so a reader does not necessarily need to read all prior chapters to understand a given one. ... this is a useful book for upper-level graduate students and Ph.D. statisticians. (Charles Heckler, Technometrics, Vol. 55 (1), February, 2013) This is a first class book. It discusses a wide range of deep issues in statistics, and although focused on topics arising in biostatistics, pharmaceuticals, and clinical trials it would make stimulating and thought-provoking reading for any statistician. ... There are exercises at the end of each chapter, and I am certainly tempted to use the book as the basis for a short course for beginning postgraduate students ... since it would open their eyes to some challenging and indeed fascinating aspects of modern statistics. (David J. Hand, International Statistical Review, Vol. 80 (1), 2012)
Author Information
Mark Chang Ph.D. is the executive director, Biostatistics and Data Management, AMAG Pharmaceuticals, with over 15 years of experience as a statistician in the field of clinical trials. He is a co-founder of the International Society for Biopharmaceutical Statistics, an executive member of ASA Biopharmaceutical Section, and a member of Expert Panel for the Networks of Centres of Excellence, Canada. He is a co-chair of Biotechnology Industry Organization Adaptive Design Working Group.
